A monoclonal antibody against human notch1 ligand-binding domain depletes subpopulation of putative breast cancer stem-like cells

Molecular Cancer Therapeutics

Volumn 11, Issue 1, 2012, Pages 77-86

  Sharma, Ankur ^a   Paranjape, Anurag N ^a   Rangarajan, Annapoorni ^a   Dighe, Rajan R ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CD24 ANTIGEN; CD44V ANTIGEN; EPIDERMAL GROWTH FACTOR; JAGGED1; MONOCLONAL ANTIBODY; NOTCH1 RECEPTOR; NOTCH1 RECEPTOR MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR HES 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; STEM CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD24; ANTIGENS, CD44; APOPTOSIS; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NEOPLASTIC STEM CELLS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION;

EID: 84863393099     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0508     Document Type: Article

References (50)

1. Artavanis-Tsakonas S, Muskavitch MAT. Notch: the past, the present, and the future. Curr Top Dev Biol 2010;92:1-29.
2. Rebay I, Fleming R, Fehon R, Cherbas L, Cherbas P, Artavanis-Tsakonas S. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. Cell 1991;67:687-99. (Pubitemid 121001482)
3. Bray S. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006;7:678-89. (Pubitemid 44268213)
4. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens J, et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000;5:207-16. (Pubitemid 30628080)
5. Kopan R, Goate A. A common enzyme connects notch signaling and Alzheimer's disease. Genes Dev 2000;14:2799-806.
6. Kopan R, Ilagan M, Xenia G. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
7. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature 1995;377:355-8.
8. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007;28:339-63. (Pubitemid 46984831)
9. Allenspach EJ, Maillard I, Aster JC, Pear W. Notch signaling in cancer. Cancer Biol Ther 2007;1:466-76.
10. Ellisen L, Bird J, West D, Soreng A, Reynolds T, Smith S, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-61. (Pubitemid 121001701)
11. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003;3:756-67. (Pubitemid 37328814)
12. Weng A, Ferrando A, Lee W, Morris IV J, Silverman L, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-71. (Pubitemid 39336870)
13. Reedijk M, Pinnaduwage D, Dickson BC, Mulligan AM, Zhang H, Bull SB, et al. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat 2008;111:439-48.
14. Parr C, Watkins G, Jiang W. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 2004;14:779-86.
15. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7. (Pubitemid 41330622)
16. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006;66:1517-25. (Pubitemid 43259933)
17. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE, et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 2007;20:685-93. (Pubitemid 46788875)
18. Dontu G, Liu S, Wicha MS. Stem cells in mammary development and carcinogenesis. Stem Cell Rev 2005;1:207-13.
19. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004;6:R605-15.
20. Kondratyev M, Kreso A, Hallett RM, Girgis-Gabardo A, Barcelon ME, Ilieva D, et al. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene. 2011 Jun 13. [Epub ahead of print].
21. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003;22:6598-608. (Pubitemid 37372340)
22. Miele L, Miao H, Nickoloff B. NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 2006;6:313-23. (Pubitemid 43961866)
23. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 2010;1806:258-67.
24. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006;66:7445-52. (Pubitemid 44289197)
25. Lewis HD, Leveridge M, Strack PR, Haldon CD, O'Neil J, Kim H, et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol 2007;14:209-19. (Pubitemid 46274429)
26. Beel A, Sanders C. Substrate specificity of g-secretase and other intramembrane proteases. Cell Mol Life Sci 2008;65:1311-34.
27. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008;27:5124-31.
28. Van Es JH, Van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, et al. Notch/-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435:959-63. (Pubitemid 40896322)
29. Yan M, Plowman GD. Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res 2007;13:7243-6.
30. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7.
31. O'Neill CF, Urs S, Cinelli C, Lincoln A, Nadeau RJ, Léon R, et al. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am J Pathol 2007;171:1023-36.
32. Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One 2010;5:e9094.
33. Li K, Li Y, Wu W, Gordon W, Chang D, Lu M, et al. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. J Biol Chem 2008;283:8046-54.
34. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010;464:1052-7.
35. Dighe R, Moudgal N. Use of [alpha]-and [beta]-subunit specific antibodies in studying interaction of hCG with Leydig cell receptors. Arch Biochem Biophys 1983;225:490-9. (Pubitemid 13010240)
36. Dighe RR, Murthy GS, Kurkalli BS, Moudgal NR. Conformation of the [alpha]-subunit of glycoprotein hormones: a study using polyclonal and monoclonal antibodies. Mol Cell Endocrinol 1990;72:63-70. (Pubitemid 20219674)
37. Dighe RR, Satyanarayana Murthy G, Raghuveer Moudgal N. Two simple and rapid methods to detect monoclonal antibodies with identical epitope specificities in a large population of monoclonal antibodies. J Immunol Methods 1990;131:229-36. (Pubitemid 20241523)
38. Gadkari RA, Sandhya S, Sowdhamini R, Dighe RR. The antigen binding sites of various hCG monoclonal antibodies show homology to different domains of LH receptor. Mol Cell Endocrinol 2007;260:23-32. (Pubitemid 44792353)
39. Cordle J, RedfieldZ C, Stacey M, van der Merwe P, Willis A, Champion B, et al. Localization of the delta-like-1-binding site in human Notch-1 and its modulation by calcium affinity. J Biol Chem 2008;283:11785-93.
40. Shawber C, Nofziger D, Hsieh J, Lindsell C, Bogler O, Hayward D, et al. Notch signaling inhibits muscle cell differentiation through a CBF1-independent pathway. Development 1996;122:3765-73. (Pubitemid 27033873)
41. Dey D, Saxena M, Paranjape AN, Krishnan V, Giraddi R, Kumar MV, et al. Phenotypic and functional characterization of human mammary stem/progenitor cells in long term culture. PLoS One 2009;4:e5329.
42. Ge C, Liu T, Hou X, Stanley P. In vivo consequences of deleting EGF repeats 8-12 including the ligand binding domain of mouse Notch1. BMC Dev Biol 2008;8:48.
43. Mittal S, Subramanyam D, Dey D, Kumar R, Rangarajan A. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer 2009;8:128.
44. Zardawi SJ, Zardawi I, McNeil CM, Millar EKA, McLeod D, Morey AL, et al. High Notch1 protein expression is an early event in breast cancer development and is associated with the HER 2 molecular subtype. Histopathology 2010;56:286-96.
45. Agrawal G, Dighe R. Critical involvement of the hinge region of the follicle-stimulating hormone receptor in the activation of the receptor. J Biol Chem 2009;284:2636-47.
46. Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther 2011;10:9-15.
47. Lleo A. Activity of gamma-secretase on substrates other than APP. Curr Top Med Chem 2008;8:9-16. (Pubitemid 351791042)
48. Gilbert CA, Daou M-C, Moser RP, Ross AH. g-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 2010;70:6870-9.
49. Takebe N, Warren R, Ivy SP. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res 2011;13:211.
50. McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Allan AL, et al. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res 2011;9:834-44.